STENTYS Reports First Quarter 2015 Revenues Rose 28%

STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing^® coronary stent, today announces revenues for the first quarter of 2015.

• Change in quarterly revenues*

*Unaudited

STENTYS recorded a remarkable sales performance during the first quarter of 2015, compared to a year ago, with strong revenue growth of 28% to €1.1 million. The growth was driven by the launch of the self-apposing Sirolimus-eluting stent, STENTYS SES, which obtained CE mark at the end of October 2014 and whose geographical deployment is underway. STENTYS SES accounted for 68% of first quarter 2015 sales, while the product it is replacing, the paclitaxel-eluting stent, accounted for just 16% of sales during the period.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments:
"The significant acceleration in revenues from a year ago shows the excellent positive reception from cardiologists to our self-apposing Sirolimus-eluting stent. We anticipate the ramp up will continue in European countries where we have a direct sales force and in other regions of the world where we market through local distributors. In 2015, the acceleration in sales should also be reinforced by the launch of MiStent SES^® as well as our new delivery catheter.”

• Upcoming financial press release

STENTYS expects to publish its revenues for the first half of 2015 on July 8, 2015.

STENTYS is listed on Comp. B of the Euronext Paris market
ISIN: FR0010949404 – Ticker: STNT